Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa
Accept poster if oral is not possible ?
Yes
Purpose
To report the anatomical and functional outcome of intravitreal dexamethasone implant in a patient with refractory macular edema secondary to retinitis pigmentosa.
Methods
Case report.
Results
A 66-year-old lady presented with blurred vision OU. She had the history of rheumatoid arthritis. The BCVA was 20/50 OD and 20/70 OS. Fundus examination showed mild pale disc, retinal vessels attenuation, mottled RPE with bony spicules on mid-periphery and macular edema OU. OCT revealed cystoid macular edema OU. The central retinal thickness was 315um OD and 496um OS respectively. FAG disclosed mottled hyperfluorescence in the mid-peripheral retina, leakage from the retinal capillaries and cystoid macular edema OU. Cystoid macular edema secondary to retinitis pigmentosa OU was suspected. The macular edema was only partially improved after treating with daily acetazolamide and monthly posterior sub-tenon injection of triamcinolone acetonide. With continued thickening of the macula and drop in visual acuity OU, she was treated with a 0.7mg of intravitreal injection of dexamethasone implant (Ozurdex). The BCVA was improved to 20/40 OD and 20/30 OS. The cystoid macular edema OU almost subsided 1 month later. The central retinal thickness decreased to 271um OD and 286um OS. However, recurrent cystoid macular edema OU developed 3 months later. The intraocular pressure was within normal limit throughout the course.
Conclusion
We present our experience in successful treatment of refractory
macular edema with intravitreal injection of dexamethasone implant resulting in clinically significant resolution of macular thickening and improvement of visual acuity.
Conflict of interest
No
Author 1
Last name
WU
Initials of first name(s)
JS
Department
Ophthalmology
City
Changhua
Country
Taiwan
Author 2
Last name
Chen
Initials of first name(s)
SN
Department
Ophthalmology
City
Changhua
Country
Taiwan
This website uses cookies to ensure you get the best experience on our website.
Learn more